Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Overview
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib is a phase 2 interventional study registered as NCT03778229 by AstraZeneca, with 367 participants enrolled, started 2019-01-09 and due to reach its primary completion in 2024-08-23. Interventions recorded: osimertinib, savolitinib and placebo. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialSavolitinib vs. Sunitinib in MET-driven PRCC.
Shares Savolitinib, Hutchmed, AstraZeneca and the tag pipeline.
- TrialSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Shares Savolitinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOsimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
Shares Hutchmed, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialHMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Shares Hutchmed, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSavolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
Shares Savolitinib, Osimertinib, AstraZeneca and the tag pipeline.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTo Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread) and the tag pipeline.